Eye damage in COVID-19. Part 1: Involvement of the eye in SARS-CoV-2 virus transmission and anterior segment complications
https://doi.org/10.21516/2072-0076-2022-15-4-156-165
Abstract
In COVID-19, eye damage may develop at any stage of the disease. Viral ribonucleic acid has been found in ocular tissues, but the role of the eye as a route of infection is yet to be substantiated. Ophthalmic manifestations may be a typical feature of COVID-19 infection or they may develop several weeks after recovery. Ophthalmologists should be aware of possible relationships of an ophthalmic pathology with SARS-CoV-2 in order to obtain targeted case history, detect the specific signs, prescribe the necessary tests and thereby reduce the spread of the infection. These relationships are also important for early diagnosis and treatment of complications that threaten the patients’ life and vision. The first part of the review focuses on the possible involvement of the eye in SARS-CoV-2 infection and the spread of infection. Clinical manifestations of the anterior segment damage are considered.
About the Authors
N. I. Kurysheva
Medical Biological University of Innovations and Continuing Education — A.I. Burnazyan Medical Biophysical Center; Ophthalmological Center, Federal Medical and Biological Agency
Russian Federation
Russian Federation
Natalia I. Kurysheva — Dr. of Med. Sci., professor, head of chair of eye diseases, head of the consultative and diagnostic department
23, Marshal Novikov St., Moscow, 123098
15, Gamaleya St., Moscow, 123098
O. A. Pererva
Medical Biological University of Innovations and Continuing Education — A.I. Burnazyan Medical Biophysical Center; Ophthalmological Center, Federal Medical and Biological Agency
Russian Federation
Russian Federation
Oksana A. Pererva — assistant of chair of eye diseases, ophthalmologist
23, Marshal Novikov St., Moscow, 123098
15, Gamaleya St., Moscow, 123098
A. D. Nikitina
Medical Biological University of Innovations and Continuing Education — A.I. Burnazyan Medical Biophysical Center; Ophthalmological Center, Federal Medical and Biological Agency
Russian Federation
Russian Federation
Anastasiya D. Nikitina — assistant of chair of eye diseases, ophthalmologist
23, Marshal Novikov St., Moscow, 123098
15, Gamaleya St., Moscow, 123098
References
1. Neroev V.V., Krichevskaya G.I., Balatskaya N.V. COVID-19 and problems of ophthalmology. Russian ophthalmological journal. 2020; 13 (4): 99–104 (in Russian). https://doi.org/10.21516/2072-0076-2020-13-4-99-104
2. Neroev V.V., Kiseleva T.N., Eliseeva E.K. Ophthalmological aspects of coronavirus infections. Russian ophthalmological journal. 2021; 14 (1): 7–14 (in Russian). https://doi.org/10.21516/2072-0076-2021-14-1-7-14
3. Takhchidi Kh.P., Takhchidi N.Kh., Movsesian M.Kh. COVID-19 in ophthalmic practice. Extreme Medicine. 2020; (4): 53–8 (in Russian). https://doi.org/10.47183/mes.2020.017
4. Kurysheva N.I. Organization of ophthalmic care in a pandemic of COVID-19. Moscow: GNC FMBC; 2021 (in Russian).
5. Kurysheva N.I., Pechenkina A.A., Goncharova A.S. Examination of patients with glaucoma during the COVID-19 pandemic. Vestnik oftal’mologii. 2021; 137 (2): 75–83 (in Russian). https://doi.org/10.17116/oftalma202113702175
6. Cheema M., Aghazadeh H., Nazarali S., et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). Can. J. Ophthalmol. 2020; 55 (4): e 125-9. https://doi.org/10.1016/j.jcjo.2020.03.003
7. Zhang X., Chen X., Chen L., et al. The evidence of SARS-CoV-2 infection on ocular surface. Ocul. Surf. 2020; 18 (3): 360–2. https://doi.org/10.1016/j.jtos.2020.03.010
8. Lu C.W., Liu X.F., Jia Z.F. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. 2020; 395 (10224): e39. https://doi.org/10.1016/S0140-6736(20)30313-5
9. Seah I., Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul. Immunol. Inflamm. 2020; 28 (3): 391–5. https://doi.org/10.1080/09273948.2020.1738501
10. World Health Organization. (2020). Origin of SARS-CoV-2, 26 March 2020. World Health Organization. Available at: https://apps.who.int/iris/handle/10665/332197
11. Chan J.F., Kok K.H., Zhu Z., et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 2020; 9 (1): 221–36. https://doi.org/10.1080/22221751.2020.1719902
12. Jiang R.D., Liu M.Q., Chen Y., et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell. 2020; 182: 50–8. https://doi.org/10.1016/j.cell.2020.05.027
13. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). February 2020. World Health Organization; 2020: 16–24.
14. World Health Organization. (2020). Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 17 January 2020. World Health Organization. Available at: https://apps.who.int/iris/handle/10665/330676
15. Loon S.-C., Teoh S.C.B., Oon L.L.E. et al. The severe acute respiratory syndrome coronavirus in tears. Br. J. Ophthalmol. 2004; 88 (7): 861–3. https://doi.org/10.1136/bjo.2003.035931
16. Chan W.M., Yuen K.S., Fan D.S., et al. Tears and conjunctival scrapings for coronavirus in patients with SARS. Br. J. Ophthalmol. 2004; 88 (7): 968–9. https://doi.org/10.1136/bjo.2003.039461
17. Yan A. Chinese expert who came down with Wuhan coronavirus after saying it was controllable thinks he was infected through his eyes. China: South China Morning Post. 2020. Available at: https://www.scmp.com/news/china/article/3047394/chinese-expert-who-came-down-wuhan-coronavirus-aftersayingit-was [Accessed 26 June 2020].
18. Lawrenson J.G., Buckley R.J. COVID-19 and the eye. Ophthalmic Physiol. Opt. 2020; 40 (4): 383–8. https://doi.org/10.1111/opo.12708
19. Ulhaq Z.S., Soraya G.V. The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid. Graefes Arch. Clin. Exp. Ophthalmol. 2020; 258 (6): 1351–2. https://doi.org/10.1007/s00417-02004695-8
20. Xia J., Tong J., Liu M., Shen Y., Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J. Med. Virol. 2020; 92 (6): 589–94. doi:10.1002/jmv.25725
21. Wu P., Duan F., Luo C., et al. Characteristics of ocular findings of patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020; 138 (5): 575. doi:10.1001/jamaophthalmol.2020.1291
22. Zhou Y., Duan C., Zeng Y., et al. Ocular findings and proportion with conjunctival SARS-COV-2 in COVID-19 patients. Ophthalmology. 2020; 127 (7): 982–3. doi:10.1016/j.ophtha.2020.04.028
23. Zhou Y., Zeng Y., Tong Y., Chen C. Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva. MedRxiv.; 2020. doi:10.1101/2020.02.11.20021956
24. Zou L., Ruan F., Huang M., et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 2020; 382 (12): 1177–9. doi:10.1056/NEJMc2001737
25. Hong N., Yu W., Xia J., et al. Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19. Acta Ophthalmol. 2020; 98 (5): e 649–55. doi:10.1111/aos.14445
26. Hu Y., Chen T., Liu M., et al. Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid in tear and conjunctival secretions of a non-conjunctivitis COVID-19 patient with obstruction of common lacrimal duct. Acta Ophthalmol. 2020; 98 (8): 859–63. doi:10.1111/aos.14456
27. Hui K.P.Y., Cheung M.C., Perera R., et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir. Med. 2020; 8 (7): 687–95. doi:10.1016/S2213-2600(20)30193-4
28. White A.J., Cheruvu S.C., Sarris M., et al. Expression of classical components of the renin-angiotensin system in the human eye. J. Renin Angiotensin Aldosterone Syst. 2015; 16 (1): 59–66. doi:10.1177/1470320314549791
29. Sungnak W., Huang N., Becavin C., et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020; 26 (5): 681–7. doi:10.1038/s41591-020-0868-6
30. Lange C., Wolf J., Auw-Haedrich C., et al. Expression of the COVID-19 receptor ACE2 in the human conjunctiva. J. Med. Virol. 2020; 92 (10): 2081–6. doi:10.1002/jmv.25981
31. Ma D., Chen C.B., Jhanji V., et al. Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea. Eye (Lond). 2020; 34 (7): 1212-9. doi:10.1038/s41433-020-0939-4
32. Leonardi A., Rosani U., Brun P. Ocular surface expression of SARS-CoV-2 receptors. Ocul. Immunol. Inflamm. 2020; 28 (5): 735–8. doi:10.1080/09273 948.2020.1772314
33. Lang J., Yang N., Deng J., et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011; 6 (8): e23710. doi:10.1371/journal.pone.0023710
34. Seah I.Y.J., Anderson D.E., Kang A.E.Z., et al. Assessing viral shedding and infectivity of tears in Coronavirus Disease 2019 (COVID-19) patients. Ophthalmology. 2020; 127 (7): 977–9. doi:10.1016/j.ophtha.2020.03.026
35. Xie H.-T., Jiang S.-Y., Xu -K.-K., et al. SARS-CoV-2 in the ocular surface of COVID-19 patients. Eye Vis (Lond). 2020; 92 (1): 23. doi:10.1186/s40662020-00189-0
36. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19. National Center for Immunization and Respiratory Diseases (NCIRD). Division of Viral Diseases. Available at: https://stacks.cdc.gov/view/cdc/86167
37. He X., Lau E.H.Y., Wu P., et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020; 26 (5): 672–5. doi:10.1038/s41591-020-0869-5
38. Chen L., Deng C., Chen X., et al. Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study. Acta Ophthalmol. 2020; 98 (8): e 951–9. doi:10.1111/aos.14472
39. Chen L., Liu M., Zhang Z., et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. Br. J. Ophthalmol. 2020; 104 (6): 748–51. doi:10.1136/bjophthalmol-2020-316304
40. Nayak B., Poddar C., Panigrahi M.K., Tripathy S., Mishra B. Late manifestation of follicular conjunctivitis in ventilated patient following COVID-19 positive severe pneumonia. Indian J. Ophthalmol. 2020; 68 (8): 1675–7. doi:10.4103/ijo.IJO_1682_20.
41. Belser J.A., Rota P.A., Tumpey T.M. Ocular tropism of respiratory viruses. Microbiol. Mol. Biol. Rev. 2013; 77 (1): 144–56. doi:10.1128/MMBR.00058-12
42. Baughman B.D., Hansemann B.K., Shah M.M., Weizer J.S. Drive-through intraocular pressure checks during the COVID-19 pandemic. J Glaucoma. 2021; 30 (3): 223–6. doi:10.1097/IJG.0000000000001748
43. Jain N., Kaur S., Kopsachilis N., Zia R. Risk of airborne COVID-19 transmission while performing Humphrey visual field testing. J. Glaucoma. 2021; 30 (3): 219–22. doi:10.1097/IJG.0000000000001771
44. Napoli P.E., Nioi M., d’Aloja E., Fossarello M. Safety recommendations and medical liability in ocular surgery during the COVID-19 pandemic: an unsolved dilemma. J. Clin. Med. 2020; 9 (5): 1403. doi:10.3390/jcm9051403
45. Casagrande M., Fitzek A., Spitzer M.S., et al. Presence of SARSCoV-2 RNA in the cornea of viremic patients with COVID-19. JAMA Ophthalmol. 2021; 139 (4): 383–8. doi:10.1001/jamaophthalmol.2020.6339
46. Aggarwal K., Agarwal A., Jaiswal N., et al. Ocular surface manifestations of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS One. 2020; 15 (11): e0241661. doi:10.1371/journal.pone.0241661
47. Sindhuja K., Lomi N., Asif M.I., Tandon R. Clinical profile and prevalence of conjunctivitis in mild COVID-19 patients in a tertiary care COVID-19 hospital: A retrospective cross-sectional study. Indian J. Ophthalmol. 2020; 68 (8): 1546–50. doi:10.4103/ijo.IJO_1319_20
48. Guo D., Xia J., Wang Y., et al. Relapsing viral keratoconjunctivitis in COVID-19: a case report. Virol. J. 2020; 17 (1): 97. doi:10.1186/s12985-020-01370-6
49. Navel V., Chiambaretta F., Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2. Am. J. Ophthalmol Case Rep. 2020; 19: 100735. doi:10.1016/j.ajoc.2020.100735
50. Otaif W., Al Somali A.I., Al Habash A. Episcleritis as a possible presenting sign of the novel coronavirus disease: A case report. Am. J. Ophthalmol. Case Rep. 2020; 20: 100917. doi:10.1016/j.ajoc.2020.100917
51. Mangana C.M., Kargacin A.B., Barraquer R.I. Episcleritis as an ocular manifestation in a patient with COVID-19. Acta Ophthalmol. 2020; 98 (8): e1056–7. doi:10.1111/aos.14484
52. Meduri A., Oliverio G.W., Mancuso G., et al. Ocular surface manifestation of COVID-19 and tear film analysis. Sci Rep. 2020; 10 (1): 20178. doi:10.1038/s41598-020-77194-9
53. Sen M., Honavar S.G., Sharma N., Sachdev M.S. COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19. Indian J. Ophthalmol. 2021; 69 (3): 488–509. doi:10.4103/ijo.IJO_297_21
54. Scalinci S.Z., Trovato Battagliola E. Conjunctivitis can be the only presenting sign and symptom of COVID-19. IDCases. 2020; 20: e00774. doi:10.1016/j.idcr.2020.e00774
55. Guan W.J., Ni Z.Y., Hu Y., et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J Med. 2020; 382 (18): 1708–20. doi:10.1056/NEJMoa2002032
56. Colavita F., Lapa D., Carletti F., et al. SARS-CoV-2 Isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection. Ann. Intern. Med. 2020; 173 (3): 242–3. doi:10.7326/M20-1176
57. Daruich A., Martin D., Bremond-Gignac D. Unilateral conjunctivitis as first presentation of Coronavirus Disease 2019 (COVID-19): A telemedicine diagnosis. J. Fr. Ophtalmol. 2020; 43 (5): e167–8. doi:10.1016/j.jfo.2020.04.001
58. Khavandi S., Tabibzadeh E., Naderan M., Shoar S. Corona virus disease-19 (COVID-19) presenting as conjunctivitis: atypically high-risk during a pandemic. Cont. Lens Anterior Eye. 2020; 43 (3): 211–2. doi:10.1016/j.clae.2020.04.010
59. Salducci M., La Torre G. COVID-19 emergency in the cruise's ship: a case report of conjunctivitis. Clin. Ter. 2020; 171 (3): e189–91. doi:10.7417/CT.2020.2212
60. Atum M., Boz A.A.E., ak r B., et al. Evaluation of conjunctival swab PCR results in patients with SARS-CoV-2 infection. Ocul. Immunol. Inflam. 2020; 28 (5): 745–8. doi:10.1080/09273948.2020.1775261
61. Lan Q.Q., Zeng S.M., Liao X., et al. A special on epidemic prevention and control: screening for novel coronavirus related conjunctivitis among the patients with coronavirus disease 2019. Zhonghua Yan Ke Za Zhi. 2020; 56 (6): 433–7. doi:10.3760/cma.j.cn112142-20200322-00213
62. Karimi S., Arabi A., Shahraki T., Safi S. Detection of severe acute respiratory syndrome Coronavirus-2 in the tears of patients with Coronavirus disease 2019. Eye (Lond). 2020; 34 (7): 1220–3. doi:10.1038/s41433-020-0965-2
63. Goel R., Arora R., Chhabra M., Kumar S. Viral shedding in tears of COVID-19 cases presenting as conjunctivitis. Indian J. Ophthalmol. 2020; 68 (10): 2308. doi:10.4103/ijo.IJO_2567_20
64. Tyagi R., Dadia S., Sharma S., et al. Ocular manifestations in Covid-19 positive patients admitted to a Tertiary care centre in Uttarakhand, India: A prospective study. International J. Health and Clinical Research. 2021; 4 (6): 225–8.
65. Bostanci Ceran B., Ozates S. Ocular manifestations of coronavirus disease 2019. Graefes Arch. Clin. Exp. Ophthalmol. 2020; 258 (9): 1959–63. doi:10.1007/s00417-020-04777-7
Review
For citations:
Kurysheva N.I., Pererva O.A., Nikitina A.D. Eye damage in COVID-19. Part 1: Involvement of the eye in SARS-CoV-2 virus transmission and anterior segment complications. Russian Ophthalmological Journal. 2022;15(4):156-165. (In Russ.) https://doi.org/10.21516/2072-0076-2022-15-4-156-165
Views:
782
Email this article 